- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04204993
Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)
Study Overview
Detailed Description
Influenza ('flu') is one of the most common causes of severe lung infection. Seasonal flu affects between 10 and 46% of the population each year and causes around 12 deaths in every 100,000 people infected. Furthermore, new strains of flu viruses emerge unpredictably every few years, causing pandemics that spread rapidly across the world. Since currently available antiviral drugs and vaccines cannot prevent these outbreaks, it is essential to be able to identify flu infections at an early stage to enable rapid treatment of individuals and implementation of public health measures.
The aim of the study is to investigate disease in volunteers deliberately infected with influenza A(H3N2), including biological markers of inflammation and immune response, and changes in physiological parameters including heart rate, respiratory rate, physical activity, oxygen saturation and electrocardiographic data during the onset of influenza infection. To achieve this, the investigators will recruit healthy volunteers and inoculate them with a flu virus, after which they will be observed in hospital while they develop a cold. Each volunteer will be given a number of devices that they will wear before and during infection. In addition, they will have blood and nasal samples taken to examine the way their immune system responds to infection. The resulting data will be analysed to see if the sensors data correlate with the onset of infection and these will be compared with measures of the immune response. Ultimately, the investigators anticipate that optimised sensor data from devices to be developed may be useful in rapidly detecting when someone is about to develop flu infection, so that they can quickly be treated and outbreaks may be identified at an early stage.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W2 1PG
- Imperial Clinical Research Facility, Imperial College London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy persons aged 18 to 55 years, able to give informed consent
Exclusion Criteria:
- Chronic respiratory disease (asthma, chronic obstructive pulmonary disease, rhinitis, sinusitis) in adulthood
- Inhaled bronchodilator or steroid use within the last 12 months
- Use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within the last 3 months
- Acute upper respiratory infection (URI or sinusitis) in the past 6 weeks
- Smoking in the past 6 months OR >5 pack-year lifetime history
- Subjects with allergic symptoms present at baseline
- Clinically relevant abnormality on chest X-ray
- Any ECG abnormality deemed clinically significant.
- Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, the elderly (>65 years), immunosuppressed persons, or those with chronic respiratory disease
- Subjects with known or suspected immune deficiency
- Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to challenge
- Known immunoglobulin A deficiency, immotile cilia syndrome, or Kartagener's syndrome
- History of frequent nose bleeds
- Any significant medical condition or prescribed drug deemed by the study doctor to make the participant unsuitable for the study
- Pregnant or breastfeeding women
- Positive urine drug screen
- Detectable baseline antibody titres against influenza challenge strains
- History of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine, or with life-threatening reactions to previous influenza vaccinations.
- Participants may only recruited if they have previously been involved in research if they have completed the earlier study and are beyond the washout period of any administered drugs or period of effect of any intervention that would cause interference for either study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Influenza A
Participants will be inoculated with Influenza A/Belgium/4217/2015 at a dose of 5x105 TCID50 in a volume of 0,5mL via intranasal drops or spray.
They will then be monitored as in-patients for 10 days with daily clinical assessment and blood, respiratory tract sampling, and sensor monitoring.
Following discharge, they will be followed up for up to 6 months post-inoculation.
|
Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest).
A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of PCR-confirmed Influenza Infections
Time Frame: Baseline to day 28
|
Nasal wash viral load by quantitative polymerase chain reaction (qPCR)
|
Baseline to day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Algorithmic Detection of Heart Rate Abnormalities
Time Frame: Baseline to day 10
|
Sensor data read-outs
|
Baseline to day 10
|
Tissue Oxygen Levels
Time Frame: Baseline to day 10
|
Sensor data read-outs
|
Baseline to day 10
|
Participant-reported Total Symptom Score
Time Frame: Day 1, Day 3 and Day 10
|
Cumulative daily symptom score derived from self-reported upper and lower respiratory and systemic symptoms by diary card using the modified Jackson's symptom scoring system.
Eight symptoms were scored: nasal obstruction, nasal discharge, sore throat, sneezing, cough, malaise, headache, and chills.
Each symptom was scored 0-3, where 0=absent, 1=mild, 2=moderate and 3=severe.
The maximum daily score is 24 and minimum daily score is 0.
|
Day 1, Day 3 and Day 10
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christopher Chiu, Imperial College London
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19HH5451
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza A H3N2
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
Emergent BioSolutionsCompletedInfluenza A H3N2 | Influenza A H1N1United States, Spain, Canada, Puerto Rico
-
HvivoPrep Biopharm LimitedCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedDetermine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2United States
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingH3N2 InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 VirusUnited States
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | OrthomyxovirdaeUnited States
-
Butantan InstituteUniversity of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...CompletedImmunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)VaccineBrazil
-
Novartis VaccinesCompletedNovel Influenza A (H1N1) | A New Flu Virus of Swine OriginChile, Colombia, Germany, Switzerland
Clinical Trials on Lumee Oxygen Platform
-
Profusa, Inc.National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingPeripheral Artery DiseaseUnited States
-
Universidade Federal de PernambucoUnknownExercise | Kidney TransplantationBrazil
-
Kafrelsheikh UniversityCompletedPeri-implant Mucositis | Dental Implant FailedEgypt
-
University of GeorgiaEmory UniversityActive, not recruitingCerebral Palsy, SpasticUnited States
-
Aristotle University Of ThessalonikiRegion Stockholm; Hospital Universitario La Fe; University of GlasgowCompleted
-
Baylor College of MedicineBioSensicsRecruitingCognitive Impairment | Dementia | Mild Cognitive Impairment | Memory LossUnited States
-
Sun Yat-sen UniversityRecruiting
-
University of LouisvilleCompleted
-
Auris Health, Inc.Terminated
-
Reproductive Medicine Associates of New JerseyCompleted